Filtered By:
Drug: Lovenox

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Venous thromboembolism in children with acute lymphoblastic leukemia
Abstract Venous thromboembolism (VTE) occurs in 0.95–36 % of children with acute lymphoblastic leukemia almost exclusively during chemotherapy. It is most commonly associated with concurrent l-asparaginase and steroid therapy, central venous line use, and inherited thrombophilia. Clinical manifestations regarding the location of VTE include central nervous system thrombosis (sinus venous thrombosis, cerebral infarct/stroke), upper-/lower-limb deep venous thrombosis, pulmonary embolism, and right atrial/intracardiac and superficial venous thrombosis and can be both symptomatic and asymptomatic. The majority of ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston Children’s Hospital Experience
Abstract Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution’s effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston...
Source: Mammalian Genome - January 8, 2015 Category: Genetics & Stem Cells Source Type: research

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF STUDY)
Publication date: Available online 21 February 2015 Source:American Heart Journal Author(s): Gregory Y.H. Lip , Jose Merino , Michael Ezekowitz , Kenneth Ellenbogen , Dmitry Zamoryakhin , Hans Lanz , James Jin , Naab Al-Saadi , Michele Mercuri , Andreas Goette We designed a prospective, randomized, open-label, blinded endpoint evaluation(PROBE) parallel group Phase 3b clinical trial comparing edoxaban (a new oral factor Xa inhibitor) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of non-valvular AF. The primary efficacy endpoint is the composite endpoints of st...
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
In conclusion, in RCTs of pharmacological VTE prophylaxis in patients undergoing THR or TKR, there was no difference in the incidence of post-operative AT among patients treated with NOACs, compared to those treated with enoxaparin. PMID: 25946985 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Squizzato A, Lussana F, Cattaneo M Tags: Thromb Haemost Source Type: research

Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy
We describe a pregnant woman with a massive CVT in early pregnancy, complicated by status epilepticus. The mother was treated with levetiracetam, lacosamide and enoxaparin throughout pregnancy. A male infant was born on pregnancy week 36, weighing 2.2 kilogram. Both levetiracetam and and lacosamide were present in cord blood in levels similar to those in maternal blood. The infant was partially breast-fed and experienced poor feeding and sleepiness, starting to resolve after two first weeks. Milk samples were drawn five days after the delivery and a blood sample from the infant three days later. Lacosamide level in milk wa...
Source: Reproductive Toxicology - July 14, 2015 Category: Toxicology Source Type: research

Heparins – DOACS – VKA
Patients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary. During hospital stage the patients get, if there are no contraindications, a medical VTE prophylaxis with low molecular weight heparin (LMWH). Whereas outpatients don`t get a prophylaxis because they are at low risk of thromboembolism. If additional risk factor for VTE exists a decision for medical VTE prophylaxis should be taken into account. In pa...
Source: Phlebologie - December 2, 2015 Category: Surgery Source Type: research

Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS)
The guidelines The new joint guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC) for non-ST-elevation acute coronary syndromes (NSTE-ACS) represent the culmination of a massive undertaking to synthesise a large body of evidence, and the guideline writing committee is to be applauded for their efforts in preparing these guidelines.1 2 As is the current standard, the online version of these guidelines was published ahead of print, and review of the electronic publication ahead of print revealed that the handling of enoxaparin was problematic.1 The problem concerned the discussion...
Source: Evidence-Based Medicine - January 22, 2016 Category: Internal Medicine Authors: Mayer, M. Tags: Clinical trials (epidemiology), Editor's choice, Drugs: cardiovascular system, Stroke, Ischaemic heart disease Perspective Source Type: research

Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
Abstract The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKA...
Source: American Journal of Cardiovascular Drugs - February 12, 2016 Category: Cardiology Source Type: research

Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study
The objectives of this study were to examine pharmacological prophylaxis against VTE among hospitalized medically ill patients and to assess demographic and clinical correlates related to VTE prophylaxis. A retrospective (1999–2010) electronic medical records study included patients aged 40 years and older hospitalized for at least 3 days, with significant medical illness or with a VTE hospitalization 30–365 days before admission. Each patient's first qualifying hospitalization was analyzed. Exclusions were if VTE treatment was started within 1 day of admission, or if warfarin (and not heparin or enoxaparin) was used. ...
Source: American Journal of Therapeutics - March 1, 2016 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Id: 41: thrombotic ramifications of ophthalmologic diagnosis of familial and acquired thrombophilia as pathoetiology for otherwise unexplained uveitis.
Conclusion When the usual pathoetiologies of uveitis are not found, ophthalmologists should screen for thrombophilia, often being the first to illuminate treatable etiologies for other thrombotic events. In our 3 patients, when the pathoetiology of uveitis could not be discerned, screening for familial and acquired thrombophilia had important therapeutic ramifications in the probands and their first degree relatives. .
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Bruce, C., Dixon, S., Glueck, C., Wang, P., Hutchins, R. Tags: Genetic [amp ] Molecular Medicine Source Type: research

Upper extremity arterial thrombus presenting at birth
We report a 36-week neonate born to a 31-year-old G2P0 woman by emergency c-section due to decreased fetal movement. The pregnancy had been uncomplicated up to that point and the mother had no significant medical history. Birth weight was 2.49 kg. Apgars were 6 and 5. Superficial skin loss and dark blue discolouration were noted along the left upper extremity and hand immediately after delivery. Fluid resuscitation and sterile saline wraps slowly improved perfusion, and the extremity pinked up over the subsequent 3 h (figure 1). She was transferred to an appropriate outside facility where Doppler ultrasound revea...
Source: Archives of Disease in Childhood - Fetal and Neonatal Edition - June 16, 2016 Category: Perinatology & Neonatology Authors: LaBore, B. P., Bedell, T. H. Tags: Journalology, Drugs: cardiovascular system, Stroke, Pregnancy, Reproductive medicine, Radiology, Clinical diagnostic tests, Radiology (diagnostics), Competing interests (ethics), Resuscitation, Trauma Images in neonatal medicine Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Cerebral Venous Sinus Thrombosis in A Patient with Sj ögren's Syndrome with Atypical Antibodies: A Case Report.
CONCLUSION: This case reports the relationship between cerebral venous sinus thrombosis and Sjögren's syndrome. It is necessary to screen autoimmune disorders in patients with cerebral venous sinus thrombosis that present with no common risk factors of venous thrombosis in order to prevent inappropriate management, and potentially adverse outcomes. PMID: 27854095 [PubMed - in process]
Source: Acta Neurologica Taiwanica - November 19, 2016 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX
The finding in patients hospitalized for acute illness was said to be"a wake-up message" that even those admitted for ischemic stroke or heart failure are at special risk for thrombosis."Heartwire from Medscape
Source: Medscape Critical Care Headlines - November 29, 2016 Category: Intensive Care Tags: Cardiology News Source Type: news

Thrombotic valvular dysfunction with transcatheter mitral interventions for postsurgical failures
ConclusionThrombotic related dysfunction post‐TMVR occurred in 15% (2/13) of patients and one patient had abnormal leaflet thickening that may have been thrombus related. Dual‐antiplatelet therapy was used in all 3 cases suggesting the possible need for oral anticoagulation postmitral valve‐in‐valve therapy. © 2017 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - February 9, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Marvin H. Eng, Adam Greenbaum, Dee Dee Wang, Janet Wyman, DNP, Heider Arjomand, Pradeep Yadav, Hassan Nemeh, Gaetano Paone, Mayra Guerrero, William O'Neill Tags: Valvular and Structural Heart Diseases Source Type: research